| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Unité Propre de Recherche de l'Enseignement Supérieur (UPRES) 2705, Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires and 2 UPRES 2704, Service de Pédiatrie, Hôpital Antoine Béclère, Université Paris Sud, Clamart, 4 Centre Hépato-Biliaire, Hôpital Paul Brousse, Villejuif and 6 Service d'Immuno-hématologie and 3 Service de Biochimie, Hôpital Lariboisière, Assistance Publique, Hôpitaux de Paris, Paris, France. 5 Division of Medical Genetics, Depts of Medicine and Genetics, University of Leicester, Leicester, UK
CORRESPONDENCE: M. Humbert, Service de Pneumologie, Centre des Maladies Vasculaires Pulmonaires, Hôpital Antoine Béclère, 157 rue de la Porte de Trivaux, 92140, Clamart, France. Fax: 33 146303824. E-mail: humbert@ipsc.u-psud.fr
Keywords: pulmonary hypertension, serotonin, type-I glycogen-storage disease
Received: July 6, 2001
Accepted January 7, 2002
This study was supported by grants from Universite Paris-Sud, Institut National de la Santé et de la Médicale (INSERM) and Association Francaise contre les Myopathies (AFM).
A case of pulmonary arterial hypertension in a patient with type-Ia glycogen-storage disease, a rare autosomal recessive disorder caused by a deficiency of glucose-6-phosphatase is reported in this study. It has been suggested that the occurrence of pulmonary arterial hypertension in type-Ia glycogen-storage disease could be due to an abnormal production of vasoconstrictive amines such as serotonin.
To test this hypothesis, plasma serotonin concentrations were prospectively measured in 13 patients with type-Ia glycogen-storage disease, one patient with severe pulmonary hypertension and type-Ia glycogen-storage disease, 16 patients displaying severe pulmonary arterial hypertension, and 26 normal healthy controls.
Elevated plasma serotonin concentrations were found in patients with either severe pulmonary arterial hypertension (38.8±7.3 nmol·L–1) or type-Ia glycogen-storage disease (36.8±11.5 nmol·L–1), as compared with controls (8.8±0.6 nmol·L–1, p<0.001). Plasma serotonin was dramatically elevated in the patient with type-Ia glycogen-storage disease and pulmonary arterial hypertension (113.4 nmol·L–1).
It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension.
This article has been cited by other articles:
|
|
 |
|
  Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Simonneau, N. Galie, L. J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, S. Gibbs, D. Lebrec, R. Speich, M. Beghetti, et al. Clinical classification of pulmonary hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 5S - 12S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert and R.C. Trembath Genetics of pulmonary hypertension: from bench to bedside Eur. Respir. J., September 1, 2002; 20(3): 741 - 749. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
